In April, Directorate General XXIV (for consumer policy and consumer health protection) of the European Commission (Brussels) suggested that the use of bovine somatotrophin (BST) should be banned in Europe. In suggesting the ban, DG XXIV cites evidence from reports published in March by two of its committees. According to the Scientific Committee on Animal Health and Animal Welfare, the use of BST for milk production increases mastitis, foot and leg problems, and other production-related diseases. It concludes, "avoidable actions which result in poor welfare, such as BST usage, should not be permitted." A second report, by the Scientific Committee on Veterinary Measures, entitled "Public Health Aspects of the Use of Bovine Somatotrophin," raises concerns that BST may affect human health. The reports states, "It is estimated that 3–10% of the human population is allergic to penicillin and other b-lactam antibiotics, which constitute the most common therapeutic treatment for clinical mastitis." According to an anonymous speaker within the commission, "DG XXIV will now suggest a ban on imports [of any produce farmed using BST]." Monsanto (St Louis, MO), the manufacturer of BST, would not speculate about a ban. A company spokesperson said, "Authorities have looked at the safety of dairy products that come from [BST] supplemented cows and have confirmed that those products are safe."